The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company Ltd. today announced that using IT-based drug discovery technologies, which entails computer-based virtual design and evaluation, they have successfully created new small molecule compounds that can inhibit cancer-causing "target proteins," and that demonstrate promise against cancers that have shown resistance to existing drugs. In order to link the results of this research to the creation of new drugs, Kowa intends to improve upon the small molecule compounds discovered through this research
Read more: http://www.worldpharmanews.com/development/4442-university-of-tokyo-s-rcast-fujitsu-and-kowa-successfully-create-promising-new-compounds-to-fight-drug-resistant-cancer